Every 8-K that Sagimet Biosciences Inc. Series A (SGMT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SGMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGMT filings page.
Sagimet Biosciences Inc. agreed to sell 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants to purchase up to 2,750,010 shares at an offering price of $9.9999 per share issuable upon exercise. The offering is expected to close October 1, 2026, subject to customary closing conditions; the company expects $107.5 million in net proceeds after underwriting discounts and commissions.
The company plans to use the proceeds together with existing cash, cash equivalents and marketable securities for a Phase 3 denifanstat acne trial, denifanstat pre-launch activities, TVB-3567 through Phase 2 topline results, its topical FASN inhibitor program through IND submission, and general corporate purposes. The warrants are immediately exercisable at $0.0001 per share. Exercise is subject to a beneficial ownership limit of 4.99%, or 9.99% at a purchaser’s election; holders may adjust the limit up to 19.99% with at least 61 days’ prior notice.
Sagimet Biosciences Inc. (SGMT) reported positive 52-week results from ASC40-304, a Phase 3 open-label denifanstat extension trial in moderate to severe acne conducted in China by license partner Ascletis BioScience Co. Ltd. Among 240 patients, treatment success was 56.7%; mean changes from ASC40-303 baseline were -71.8% in total lesion count, -76.9% in inflammatory lesion count and -66.9% in non-inflammatory lesion count. Success required a 2-point IGA reduction from baseline to 0 or 1.
All 240 extension patients received denifanstat 50 mg once daily for up to 40 weeks; the 116 originally assigned denifanstat had up to 52 weeks of total exposure. Effective September 30, 2026, Sagimet suspended and terminated its ATM prospectus supplement. It will make no Series A common stock sales under the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed; the agreement remains in effect. The company said its cash position was expected to fund current operations through 2028 and through readout of its U.S. Phase 3 acne trial.
Sagimet Biosciences Inc. reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for its fatty acid synthase inhibitor denifanstat in moderate to severe acne. The FDA also issued a “Study May Proceed” letter for a planned Phase 3 clinical trial of denifanstat in this indication.
This clearance allows Sagimet Biosciences to move forward with Phase 3 testing of denifanstat in patients with moderate to severe acne, advancing the program into a late-stage clinical development phase in the United States.
Sagimet Biosciences Inc. reported second-quarter 2026 results and pipeline progress focused on dermatology. For the quarter ended June 30, 2026, the company recorded a net loss of $13.9 million, compared with $10.4 million a year earlier, as it increased R&D investment.
Research and development expense was $11.5 million versus $7.2 million, while general and administrative expense was broadly flat at $4.3 million. A March–April 2026 equity financing generated $175.0 million of gross proceeds, lifting cash, cash equivalents and marketable securities to $257.6 million as of June 30, 2026, which Sagimet expects to fund operations through 2028, including Phase 3 denifanstat acne data readout and NDA submission.
Denifanstat met all primary and secondary endpoints in a Phase 3 acne trial in China, where an NDA was accepted in December 2025. Sagimet plans a U.S. registrational Phase 3 acne trial in the second half of 2026 and is running a first-in-human Phase 1 trial of follow-on FASN inhibitor TVB-3567.
Sagimet Biosciences Inc. furnished an updated investor presentation describing its strategy around fatty acid synthase (FASN) inhibition in dermatology and metabolic disease. Lead oral FASN inhibitor denifanstat showed proof-of-concept in multiple settings, including a Phase 3 acne trial in China that met all primary and secondary endpoints and supported a denifanstat new drug application accepted by the China NMPA in December 2025.
The company plans a US Phase 3 trial of denifanstat in moderate to severe acne in the second half of 2026, contingent on regulatory consultation, and highlights a completed Phase 2b trial in MASH that met histology primary and multiple secondary endpoints and received FDA Breakthrough Therapy designation. Follow-on FASN inhibitor TVB-3567 is in a first-in-human Phase 1 study begun June 2025, with a Phase 2 acne trial anticipated in 2026, subject to regulatory feedback.
Sagimet reports intellectual property coverage for denifanstat and TVB-3567 extending into the 2030s and beyond. It cites $104 of cash, cash equivalents and marketable securities as of March 31, 2026 and an announced $175M underwritten Series A common stock offering in April 2026, which together are expected to fund operations through 2028 and through the planned denifanstat US Phase 3 acne readout.
Sagimet Biosciences Inc. reported a Board change and the results of its 2026 Annual Meeting of Stockholders. Director Tim Walbert resigned from the Board effective June 12, 2026, citing other commitments and no disagreements with the company.
At the virtual annual meeting, held June 12, 2026, with 32,017,613 Series A common shares outstanding as of the April 17, 2026 record date, stockholders elected Class III directors Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D. to serve until the 2029 annual meeting, and ratified KPMG LLP as independent registered public accounting firm for the 2026 fiscal year.
Sagimet Biosciences Inc. reported new long-term equity awards for three senior officers. On May 28, 2026, the company granted stock options and performance-based restricted stock units (PSUs) under its 2023 Stock Option and Incentive Plan to its CEO, CFO, and Chief Legal and Administrative Officer.
CEO David Happel received 300,000 options and 300,000 PSUs, CFO Thierry Chauche received 50,000 options and 50,000 PSUs, and Chief Legal and Administrative Officer Elizabeth Rozek received 100,000 options and 100,000 PSUs. Each option has an exercise price of $7.27 per share, matching the Series A common stock closing price on the grant date, and vests in equal installments over 48 months.
The PSUs will be earned based on the company’s achievement of specified regulatory milestones. For each officer, one-third of the earned PSUs will vest on the date the Compensation Committee determines that these milestones were achieved, with the remaining two-thirds vesting in two equal installments on the first and second anniversaries of that determination date.
Sagimet Biosciences reported first quarter 2026 results alongside major financing and pipeline updates. The company completed a $175 million equity financing in April 2026 and now expects its cash, cash equivalents and marketable securities to fund operations through 2028, including data readout from a planned Phase 3 acne trial of denifanstat.
For the quarter ended March 31, 2026, Sagimet reported a net loss of $10.7 million compared with $18.2 million a year earlier, as total operating expenses fell to $11.7 million from $19.9 million. Net loss per share improved to $0.33 from $0.56, with weighted-average shares of about 32.6 million. Cash, cash equivalents and marketable securities were $104.5 million as of March 31, 2026, down modestly from $113.1 million at year-end 2025.
Sagimet Biosciences Inc. entered into an underwriting agreement for an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share. The Company expects to receive $164.5 million in net proceeds after underwriting discounts and commissions.
The Company plans to use the proceeds, together with existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, advance TVB-3567 through Phase 2 topline results, move a topical FASN inhibitor to IND submission, and for general corporate purposes including additional clinical development, working capital and operating expenses.
Sagimet Biosciences Inc. furnished an updated investor slide presentation as an exhibit to a current report. The presentation, dated April 27, 2026, is attached as Exhibit 99.1 and will be used in meetings with investors.
The materials are provided under Item 7.01 as information that is being furnished, not deemed filed under the Exchange Act, and are only incorporated by reference in other filings if specifically referenced.
Sagimet Biosciences Inc. furnished preliminary financial data and strategic updates. The company estimates unaudited cash, cash equivalents and marketable securities of approximately $104.5 million as of March 31, 2026, noting this figure may change after normal closing procedures and review.
Sagimet plans a U.S. Phase 3 clinical trial of its FASN inhibitor denifanstat for moderate to severe acne, expected to start in the second half of 2026, following positive Phase 3 safety data from its license partner in China. A first-in-human Phase 1 trial of FASN inhibitor TVB-3567 is ongoing.
The company is prioritizing its dermatology franchise in capital allocation and plans to advance its MASH program only if it secures non-dilutive funding. Sagimet will host a virtual KOL event on April 30, 2026 at 2 p.m. ET to discuss denifanstat’s acne development.
Sagimet Biosciences Inc. reported a leadership transition in its clinical organization. On April 20, 2026, Chief Medical Officer Eduardo Martins, M.D., D.Phil. retired from his officer role and will continue supporting the company as an external scientific advisor.
The company simultaneously appointed Andreas Grauer, M.D. as its new Chief Medical Officer, effective the same date. Dr. Grauer brings prior CMO experience at several biopharmaceutical companies and a long tenure in drug development roles, while maintaining an academic appointment at the University of Heidelberg Medical School.
Sagimet Biosciences reported 2025 results and outlined progress across its MASH, acne and oncology programs. For 2025, total operating expenses were $56.9 million and net loss was $51.0 million, compared with a $45.6 million net loss in 2024. Fourth-quarter 2025 net loss was $9.6 million versus $16.2 million a year earlier. Cash, cash equivalents and marketable securities were $113.1 million as of December 31, 2025, which the company expects will fund operations through the third quarter of 2027.
Clinically, denifanstat continued to show strong Phase 2b data in MASH, including statistically significant improvements in steatohepatitis and fibrosis, and positive safety. A Phase 1 pharmacokinetic trial of a denifanstat/resmetirom combination was completed, with a Phase 2 trial in MASH cirrhosis (F4) planned for the second half of 2026. In acne, partner Ascletis’ Phase 3 trial of denifanstat met all primary and secondary endpoints, and China’s regulator accepted an NDA for moderate to severe acne in 2025.
Sagimet also highlighted its follow‑on FASN inhibitor TVB‑3567, now in a first‑in‑human Phase 1 trial for acne, and exploratory oncology work targeting FASN‑dependent tumors, supporting a multi‑indication pipeline built around FASN inhibition.
Sagimet Biosciences Inc. filed a current report describing new communications to investors about a key development in its partnered acne program. The company issued a press release noting that Ascletis Pharma reported positive topline results from an open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne.
Sagimet also refreshed its investor slide presentation, which will be used in future investor meetings. Both the press release and the updated presentation are furnished as exhibits and are not treated as filed financial statements under securities law.
Sagimet Biosciences Inc. reported that it has updated its investor slide presentation and made it available as a new version for use in upcoming meetings with investors. The company also announced positive results from a Phase 1 pharmacokinetic trial evaluating a combination of its oral once-daily fatty acid synthase inhibitor, denifanstat, with a thyroid hormone receptor beta agonist, resmetirom. These early-stage data relate to how the drugs are processed in the body when used together and are being shared through a press release and updated investor materials attached as exhibits.
Sagimet Biosciences Inc. entered into a license agreement with Assia Chemical Industries Ltd., doing business as TAPI Technology & API Services, a subsidiary of Teva Pharmaceutical Industries. TAPI granted Sagimet a global, exclusive license to certain intellectual property covering innovative forms of TAPI’s resmetirom active pharmaceutical ingredient for Sagimet’s technical evaluation and manufacture.
If Sagimet elects to proceed after an evaluation period, the license also covers further development of a fixed-dose combination product containing denifanstat and resmetirom. Sagimet previously made a non-refundable up-front payment of $2.5 million to TAPI upon execution of a term sheet, and TAPI may be eligible for low single-digit royalties plus up to $5.5 million in additional manufacturing-related milestone payments. The agreement runs until specified TAPI know-how is no longer confidential or the last TAPI patent expires, unless terminated earlier under its terms.
Sagimet Biosciences (SGMT) furnished an update via Form 8-K. The company announced it issued a press release with financial results for the quarter ended September 30, 2025, and provided an updated investor presentation. Both materials are included as Exhibits 99.1 and 99.2 and are incorporated by reference.
The company noted that the press release and investor presentation are being furnished, not filed, under the Exchange Act. Representatives may use the updated presentation in meetings with investors.
Sagimet Biosciences (SGMT) furnished an updated investor presentation as Exhibit 99.1 to a Form 8-K. The company states that the materials in Item 7.01 and Exhibit 99.1 are being furnished and are not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth in a future filing.
Representatives may use the updated presentation in meetings with investors from time to time. The filing is an informational Reg FD update and does not announce a transaction or financial results.
Sagimet Biosciences Inc. reported that its Board of Directors, following a recommendation from the Audit Committee, approved a change in independent auditors. Effective August 18, 2025, KPMG LLP was appointed as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 and related interim periods, and Deloitte & Touche LLP was dismissed from this role.
The company states that Deloitte’s audit reports on the financial statements for the years ended December 31, 2024 and 2023 contained no adverse opinions, disclaimers of opinion, or qualifications, and that there were no disagreements with Deloitte on accounting principles, financial statement disclosure, or audit procedures during those periods and through August 18, 2025. Sagimet also notes that during the same periods it did not consult KPMG on specific accounting transactions or anticipated audit opinions before this appointment.
Sagimet Biosciences, Inc. reported the entry into a material definitive agreement on August 14, 2025. The filing lists a Sales Agreement dated August 14, 2025 between Leerink Partners LLC and Sagimet Biosciences Inc., and includes an opinion from Goodwin Procter LLP and their consent. The document is an 8-K disclosing a material transaction; no financial terms, offering amounts, or other operational details are provided in the text supplied.
Sagimet Biosciences announced it has furnished a press release reporting its financial results for the quarter ended June 30, 2025 and has updated its investor slide presentation. The press release is furnished as Exhibit 99.1 and the slide deck as Exhibit 99.2.
Both exhibits are described in the report as being furnished rather than filed, and therefore are not deemed filed or incorporated by reference into other SEC filings except if expressly referenced. Company representatives will use the updated presentation in meetings with investors.